In a nutshell This study wanted to find out if patients with melanoma who had immune system side effects after treatment with nivolumab (Opdivo) had better outcomes than patients without side effects. The study found that the patients who had side effects from using nivolumab ended up with better responses to treatment and...
Read More
In a nutshell This study wanted to find out if patients with melanoma who had immune system side effects after treatment with nivolumab (Opdivo) had better outcomes than patients without side effects. The study found that the patients who had side effects from using nivolumab ended up with better responses to treatment and...
Read More
In a nutshell This study wanted to find out if treating patients who had melanoma cancer that had spread with PV-10 resulted in better outcomes. The study found that treating melanoma tumors that had spread with PV-10 resulted in the tumors being destroyed, with very few side effects. Some background Melanoma cancer can commonly spread from the...
Read MoreIn a nutshell This study wanted to find out how many cancer patients who were receiving treatments which target the immune system end up with thyroid problems. The study found that there were higher numbers of these patients experiencing issues with the thyroid than previously reported. Some background There are a number of options for treatment of...
Read More
In a nutshell This study wanted to find out which combination of medication is better for treatment of advanced melanoma, paclitaxel (Taxol), paclitaxel plus trametinib (Mekinist), or paclitaxel plus pazopanib (Votrient). The study found that paclitaxel and trametinib had the best response, but had a lot of side effects, and there was no effect on...
Read MoreIn a nutshell This trial aims to evaluate the safety and effectiveness of pembrolizumab (Keytruda) in stopping cancer coming back, compared to placebo in participants with surgically resected high-risk stage II melanoma. The main outcome that will be measured is how long patients go without cancer coming back (recurrence-free...
Read More
In a nutshell This study wanted to find out how well two chemotherapy drugs, fotemustine (Muphoran) and temozolomide (Temodar) work in treating melanoma that had spread to other organs (metastatic melanoma). The study found that some of the patients responded to this combination of medications. Some background Metastatic melanoma can often be...
Read More
In a nutshell This study wanted to give an outline on what the current guidelines are for treating skin melanoma. The study overall said that surgery is the best way to remove the melanoma. Removing wide area around the melanoma is a good idea to make sure all the cancer cells are removed. Some background Skin melanoma can sometimes be...
Read More
In a nutshell This study wanted to see how long patients with melanoma would take to relapse (stop responding) when treated with dabrafenib (Tafinlar) plus tramentinib (Mekinst) after surgery. The study found that after four-years, the relapse rate was 59% compared to 40% in those who did not use the medications after surgery. Some background A...
Read More
In a nutshell This study wanted to see if using a different BRAF inhibitor was effective in the treatment of patients with melanoma. The study found that retreating with a slightly different BRAF inhibitor worked well. Some background Around 50% of patients with melanoma that has spread have a mutation in one of their genes. This gene is...
Read More
In a nutshell This study wanted to find out which medications are better for treating advanced melanoma; nivolumab (Opdivo) plus ipilimumab (Yervoy), nivolumab alone, or ipilimumab alone. The study found that using the combination of nivolumab and ipilimumab was more effective than using nivolumab alone, with the least...
Read More
In a nutshell This study wanted to find out which treatment for melanoma cancer worked better, encorafenib (Braftovi) + binimetinib (Mektovi), encorafenib alone, or vemurafenib (Zelboraf) alone. The study found that encorafenib + binimetinib worked well and was safe, compared to vemurafenib and encorafenib. Some background In about 50% of patients...
Read More
